PBAC's latest decision on Oxycodone hydrochloride + naloxone hydrochloride: Recommended (2015). Considered for Chronic severe disabling pain unresponsive to non-narcotic analgesics. Three additional modified-release tablet strengths (2.5 mg/1.25 mg, 15 mg/7.5 mg, and 30 mg/15 mg) are sought for listing under the same conditions as existing strengths.
PBAC outcome
Recommended
Restricted
ICER (AUD/QALY)
Not modelled
no economic evaluation
Submissions
2
first 2015
Submissions
2
2015 → 2015
Eligible population
Patients with chronic severe disabling pain unresponsive to non-narcotic analgesics, including those with malignant neoplasia and elderly patients with musculoskeletal pain.
Therapy area
Pain
Line of therapy
Not applicable
Evidence base
Other
Economic model
Not modelled
ICER note
This is a minor submission for additional strengths of an already-listed product; no economic evaluation or ICER was conducted.